Lakefront Biotherapeutics (LKFT) Divestments (2021 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Divestments for 6 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Divestments fell 91.83% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at -$11.0 million (down 143.72% YoY), while the FY2025 annual figure was $22.6 million, up 336.52% from the prior year.
• Divestments advanced to $2.7 million in Q1 2026 per LKFT's latest filing, from $1.9 million in the prior quarter.
• Across five years, Divestments topped out at $33.6 million in Q1 2025 and bottomed at -$1.0 billion in Q1 2022.
• Historically, Divestments has averaged -$122.2 million across 5 years, with a median of -$1.5 million in 2024.
• Annual changes were most pronounced in 2022 — Divestments sank 3126.65% — and 2025, when it jumped 2408.57%.
• Lakefront Biotherapeutics' Divestments stood at -$1.0 billion in 2022, then soared by 70.43% to -$309.8 million in 2023, then soared by 100.43% to $1.3 million in 2024, then surged by 40.23% to $1.9 million in 2025, then surged by 45.28% to $2.7 million in 2026.
• Business Quant data shows LKFT's Divestments at $2.7 million in Q1 2026, $1.9 million in Q4 2025, and $9.4 million in Q3 2025.